Taysha Gene Therapies
Advances TSHA-102, an AAV9 gene therapy in pivotal testing for Rett syndrome.
Something off on this page? Send us feedback.
Profile
Develops AAV-based gene therapies for severe monogenic CNS diseases, with TSHA-102 for Rett syndrome as the lead pivotal program. The company is pre-commercial, concentrated in the United States, and depends on clinical readouts, FDA feedback, manufacturing work, and capital access before any approved launch.
Develops AAV-based gene therapies for severe monogenic diseases of the central nervous system. The operating focus is TSHA-102, an intrathecal AAV9 program designed to deliver functional MECP2 for Rett syndrome, while other early-stage CNS programs remain secondary or partnership-dependent.
Started from a UT Southwestern gene-therapy collaboration and an initially broad pipeline, the company has narrowed around TSHA-102. Public materials list pivotal-stage development and several U.S., European, and U.K. regulatory designations for the program.
Remains pre-commercial, with no product-sales revenue and operations funded through equity, debt, and prior Astellas transactions. The business depends on clinical outcomes, FDA feedback, manufacturing readiness, capital access, and eventual commercialization capacity if approval is obtained.
Company facts
Key statistics
Year to date +9.9% · Average volume (30d) 2.4M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 21, 2026 | Goldman Sachs | Reiterate | Buy | $11 | $13 |
| Jun 30, 2026 | Robert W. Baird | Target | $12 | $15 | |
| Jun 23, 2026 | Pivotal Research | Target | $14 | ||
| Jan 6, 2026 | Raymond James | Target | $9 | $13 | |
| Jan 5, 2026 | Wells Fargo | Reiterate | Overweight | $11 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.11 | −$0.13 | −14.8% | $680.0K | $0 | −100.0% | −4.04% |
| May 6, 2026Q1 FY26 | −$0.10 | −$0.12 | −20.0% | $755.6K | — | — | −4.44% |
| Mar 19, 2026Q4 FY25 | −$0.11 | −$0.08 | +27.3% | $2.2M | $5.5M | +144.5% | −3.51% |
| Nov 4, 2025Q3 FY25 | −$0.09 | −$0.09 | 0.0% | $1.9M | — | — | −5.62% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $2.0M | $0 | $5.5M | $0 | $0 | |
| Gross profit | $2.3M | $2.0M | −$286.0K | $5.2M | −$295.0K | $0 | |
| Operating income | −$21.4M | −$26.8M | −$34.0M | −$28.3M | −$43.5M | −$47.3M | |
| Net income | −$21.5M | −$26.9M | −$32.7M | −$27.9M | −$42.4M | −$46.6M | |
| Diluted EPS | −$0.08 | −$0.09 | −$0.09 | −$0.08 | −$0.12 | −$0.13 | |
| Gross margin | 100.0% | 100.0% | — | 94.5% | — | — | |
| Operating margin | -930.5% | -1,347.1% | — | -516.0% | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $2.5M · FY23 $15.5M · FY24 $8.3M · FY25 $9.8M
Balance sheet, Jun 30, 2026Cash & short-term investments $455.4M · Total debt $55.6M · Total assets $470.4M · Shareholders' equity $387.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 319.86M · Float 265.14M · 82.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 23.56M | 7.36% | 13F | May 15, 2026 |
| Goldman Sachs Group Inc | 22.37M | 6.99% | 13F | May 15, 2026 |
| Avoro Capital Advisors LLC | 21.70M | 6.78% | 13F | May 15, 2026 |
| RTW Investments, LP | 20.69M | 7.00% | 13G | May 15, 2026 |
| BlackRock, Inc. | 18.37M | 5.74% | 13F | May 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 10, 2026 | Sukumar Nagendran | director, officer: President and Head of R&D | −200,000 | $6.24 |
| Apr 10, 2026 | Sukumar Nagendran | director, officer: President and Head of R&D | −200,000 | $4.46 |
| Feb 4, 2026 | Kamran Alam | officer: CHIEF FINANCIAL OFFICER | −1,655 | $4.52 |
| Jan 26, 2026 | Kamran Alam | officer: CHIEF FINANCIAL OFFICER | −23,849 | $4.61 |
| Jan 23, 2026 | Kamran Alam | officer: CHIEF FINANCIAL OFFICER | −78,968 | $4.75 |
Peers
- Neurogene
Closest Rett gene-therapy rival with NGN-401
- Acadia Pharmaceuticals
Commercial Rett incumbent through DAYBUE
- Ultragenyx Pharmaceutical
Rare neurogenetic and orphan-launch peer
- Sarepta Therapeutics
Commercial AAV genetic-medicine benchmark
- REGENXBIO
AAV platform and one-time rare-disease peer
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies | $5.87 | +1.73% | $1.85B | — | — | 336.5 | −100.0% |
| Neurogene | $36.58 | +0.16% | $578.0M | — | — | — | — |
| Acadia Pharmaceuticals | $29.17 | +0.18% | $4.98B | 13.1 | 32.7 | 4.4 | +16.4% |
| Ultragenyx Pharmaceutical | $25.68 | +0.27% | $2.52B | — | — | 3.5 | +28.5% |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| REGENXBIO | $9.65 | −0.21% | $499.4M | — | — | 2.9 | +405.7% |
| Median | 13.1 | 29.5 | 3.2 | +22.5% |